Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones

1993 ◽  
Vol 36 (2) ◽  
pp. 108-114 ◽  
Author(s):  
Maarten P. R. Tas ◽  
Peter J. Simons ◽  
Fons J. M. Balm ◽  
Hemmo A. Drexhage
Keyword(s):  
Dendritic Cells ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Thymic Hormones

Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.

1989 ◽  
Vol 7 (6) ◽  
pp. 761-768 ◽  
Author(s):  
E E Vokes ◽  
W R Panje ◽  
R L Schilsky ◽  
R Mick ◽  
A M Awan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Poor Prognosis ◽  
Local Therapy ◽  
Complete Response ◽  
Synergistic Activity ◽  
Dose Levels ◽  
Concomitant Radiotherapy

Hydroxyurea and fluorouracil (5-FU) are active cytotoxic drugs in head and neck cancer and have shown synergistic activity in vitro. Both drugs also act as radiosensitizers. Therefore, we administered radiotherapy at daily fractions of 180 to 200 cGy with simultaneous continuous infusion 5-FU at 800 mg/m2/d and escalating daily doses of hydroxyurea for five days. Cycles were repeated every other week until completion of radiotherapy. Thirty-nine inoperable patients were treated at six dose levels of hydroxyurea ranging from 500 mg to 3,000 mg orally daily. Little effect of hydroxyurea on the WBC or platelet count was noted in patients receiving less than 2,000 mg daily, whereas both parameters decreased progressively in patients receiving 2,000 mg daily or more. Mucositis occurred at all dose levels, requiring frequent dose reduction of 5-FU; however, in patients receiving a daily hydroxyurea dose of 2,000 mg or less, the median weekly 5-FU dose administered was 1,725 mg/m2 (86% of the intended 5-FU dose), whereas at daily hydroxyurea doses exceeding 2,000 mg, the median weekly 5-FU dose decreased to 1,133 mg/m2 (57%) (P = .001). Of 15 evaluable patients with recurrent disease after prior local therapy only one failed to respond; six had a complete response (CR), and eight a partial response (PR). Of 17 evaluable patients without prior local therapy, 12 had a CR, with no patient developing recurrence in the irradiated field to date; five patients had a PR. We conclude that the recommended dose of hydroxyurea in this regimen is 2,000 mg daily. That dose will cause mild to moderate myelosuppression and will allow for delivery of greater than 80% of the intended 5-FU dose. The activity of this regimen in poor-prognosis head and neck cancer exceeds 90%; its further investigation in previously untreated patients is warranted.

scholarly journals Ionizing radiation affects the composition of the proteome of extracellular vesicles released by head-and-neck cancer cells in vitro

2019 ◽  
Vol 60 (3) ◽  
pp. 289-297 ◽  
Author(s):  
Agata Abramowicz ◽  
Anna Wojakowska ◽  
Lukasz Marczak ◽  
Malgorzata Lysek-Gladysinska ◽  
Mateusz Smolarz ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Ionizing Radiation ◽  
Head And Neck ◽  
Cancer Cells ◽  
Extracellular Vesicles ◽  
Neck Cancer

scholarly journals Biology of plasmacytoid dendritic cells in head and neck cancer

2017 ◽  
Vol 28 ◽  
pp. xi25-xi26
Author(s):  
V. Koucký ◽  
K. Hladíková ◽  
S. Partlová ◽  
J. Bouček ◽  
M. Zábrodský ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Plasmacytoid Dendritic Cells

scholarly journals Correction: In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance

2020 ◽  
Vol 19 (9) ◽  
pp. 1955-1955
Author(s):  
Abu Syed Md Anisuzzaman ◽  
Abedul Haque ◽  
Dongsheng Wang ◽  
Mohammad Aminur Rahman ◽  
Chao Zhang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Antitumor Activity ◽  
Head And Neck ◽  
Neck Cancer ◽  
Synergistic Antitumor Activity

PO-0942 EXPRESSION OF THE EGFR/HER2/PAKT PATHWAY IN VITRO AND IN VIVO IS AFFECTED BY HYPOXIA IN HUMAN HEAD AND NECK CANCER

2012 ◽  
Vol 103 ◽  
pp. S371
Author(s):  
J. Bussink ◽  
J.H.A.M. Kaanders ◽  
D.L. Wheeler ◽  
A.J. van der Kogel ◽  
M. Iida ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Human Head

Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro

2014 ◽  
Vol 90 (8) ◽  
pp. 678-686 ◽  
Author(s):  
Iris Eke ◽  
Mirjam Ingargiola ◽  
Claudia Förster ◽  
Leoni A. Kunz-Schughart ◽  
Michael Baumann ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Cells ◽  
Neck Cancer ◽  
External Irradiation

scholarly journals Photodynamic therapy suppresses the migration and invasion of head and neck cancer cells in vitro

Oral Oncology ◽  
2007 ◽  
Vol 43 (4) ◽  
pp. 358-365 ◽  
Author(s):  
Ting-Hua Yang ◽  
Chin-Tin Chen ◽  
Cheng-Ping Wang ◽  
Pei-Jen Lou
Keyword(s):  
Head And Neck Cancer ◽  
Photodynamic Therapy ◽  
Head And Neck ◽  
Cancer Cells ◽  
Neck Cancer ◽  
Migration And Invasion

Tyrosine kinase profiling guides combined therapeutic strategies in head and neck cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6078-6078
Author(s):  
R. Rodríguez-Barrueco ◽  
M. Ortíz-Ruiz ◽  
J. J. Cruz ◽  
A. Ocana ◽  
A. Pandiella
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cell Lines ◽  
Neck Cancer ◽  
Tyrosine Kinases ◽  
Egf Receptor ◽  
Drug Combinations ◽  
Metastatic Setting

6078 Background: Squamous cell carcinoma of the head and neck (SCCHN) is still an incurable disease in the metastatic setting. A particular subgroup of proteins implicated in the head and neck cancer are the tyrosine kinases (TK). Therapeutic inhibition of several of them including the EGF receptor with cetuximab in combination with radiotherapy or chemotherapy has shown to be clinically useful. Beyond EGFR, oncogenic activation of other TKs may be implicated in the genesis/progression of SCCHN. In this context, the identification of the TKs activated in SCCHN is a must in order to adequately target these kinases with already available inhibitors. Methods: Here we have investigated activated tyrosine kinases in head and neck cancer tumors derived from patients using a human phospho protein array for 42 receptor tyrosine kinases (RTK). Western-blot experiments were performed to validate each phospho RTK in tumors from patients. The same approach was followed in a series of head and neck cancer cell lines. In vivo xenografted models were used to study the antiproliferative effect of the combination of specific TK inhibitors against them. Results: TK receptors of the EGF and the VEGF family were the mostly activated in tumors derived from patients. 90% of patients revealed high pEGFR content. In addition, other EGFR/HER family receptors, such as HER3, were also activated (phosphorylated) in samples from patients. These data were corroborated in the SCCHN cell lines. In these cells, other RTK signalling intermediates were also active. Particularly, the Akt and FAK kinases. Combination of the anti-EGFR-HER2 TK inhibitor lapatinib with dasatinib (that targets FAK) was synergistic in vitro. Combination of lapatinib with the anti-VEGFR TK inhibitor pazopanib was inefficient in vitro, but resulted in a better trend in response in the in vivo xenografted models, as compared to the action of the single agents. Conclusions: Rational target drug combinations should be based on the identification of activated TK receptors or downstream signalling molecules. In head and neck cancer combination strategies using anti-EGFR/HER, anti-FAK, and anti-VEGFR compounds increases the action of individual treatments. These results open the door for future clinical development of these drug combinations. No significant financial relationships to disclose.

scholarly journals Impairment of T-Cell Activation in Head and Neck Cancer In Situ and In Vitro

1999 ◽  
Vol 125 (1) ◽  
pp. 82 ◽  
Author(s):  
Stephan Lang ◽  
Theresa L. Whiteside ◽  
Annette Lebeau ◽  
Reinhard Zeidler ◽  
Brigitte Mack ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
T Cell ◽  
Head And Neck ◽  
T Cell Activation ◽  
Neck Cancer ◽  
Cell Activation
Sign in / Sign up

Export Citation Format

Share Document